Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
CTXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $26.77
Previous CloseN/A
Volume111.57K
Average Volume (3M)138.71K
Market Cap
$12.63M
Enterprise Value$91.73M
Total Cash (Recent Filing)$29.07M
Total Debt (Recent Filing)$582.30K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 08, 2025EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding8,593,433
10 Day Avg. Volume54,484
30 Day Avg. Volume138,713
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap7.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$9.00Price Target Upside512.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Citius Pharmaceuticals News
PremiumCompany Announcements
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMino-Lok achieved its primary endpoint in the P3 study, significantly delaying or preventing catheter failure compared to the standard of care.
Product Launch PotentialThe potential launch of Lymphir through Citius Oncology, in which Citius holds a 93% ownership stake, could provide near-term revenue.
Regulatory GuidanceCitius Pharma has received clear, constructive, and actionable guidance from the FDA for the path to NDA submission for Mino-Lok.
Bears Say
Regulatory And Financial RisksRisks include failure of clinical trials, regulatory requirements for additional studies, and potential need to raise additional funds under poor market conditions.
Revenue RiskTimelines for the NDA submission of Mino-Lok are uncertain, leading to an increase in the revenue risk adjustment.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $1.41 and its highest was $26.77 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Citius Pharmaceuticals’s market cap is $12.63M.
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Feb 14, 2025. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.365 by $0.065.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate is 1.3.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 8,593,433 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.365. Following the earnings report the stock price went down -8.178%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Currently, no hedge funds are holding shares in CTXR
---
Citius Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (512.24% Upside)
$9.00 (512.24% Upside)
Blogger Sentiment
Bullish
CTXR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 12.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.66%
12-Months-Change
Fundamentals
Return on Equity
-52.85%
Trailing 12-Months
Asset Growth
23.93%
Trailing 12-Months
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. (CTXR) is a late-stage biopharmaceutical company focused on developing and commercializing critical care products. The company operates primarily in the pharmaceuticals sector, aiming to address unmet medical needs in areas such as anti-infectives, cancer care, prescription skincare, and unique prescription products. Its core products include Mino-Lok, a treatment for catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the relief of hemorrhoids.
---
CTXR Stock 12 Month Forecast
Average Price Target
$9.00
▲(512.24% Upside)
Technical Analysis
Best Analysts Covering CTXR
1 Year
1 Year Success Rate
10/26 ratings generated profit
1 Year Average Return
-1.14%
upgraded a buy rating 3 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -1.14% per trade.
---